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ABSTRACT
Objectives: To investigate use of dual tests for
Chlamydia trachomatis and Neisseria gonorrhoeae on
samples collected through the National Chlamydia
Screening Programme (NCSP) in England.
Design and setting: During May–July 2013, we
delivered an online survey to commissioners of sexual
health services in the 152 upper-tier English Local
Authorities (LAs) who were responsible for
commissioning chlamydia screening in people aged
15–24 years.
Main outcome measures: (1) The proportion of
English LAs using dual tests on samples collected by the
NCSP; (2) The estimated number of gonorrhoea tests
and false positives from samples collected by the NCSP,
calculated using national surveillance data on the number
of chlamydia tests performed, assuming the gonorrhoea
prevalence to range between 0.1% and 1%, and test
sensitivity and specificity of 99.5%.
Results: 64% (98/152) of LAs responded to this
national survey; over half (53% (52/98)) reported
currently using dual tests in community settings. There
was no significant difference between LAs using and not
using dual tests by chlamydia positivity, chlamydia
diagnosis rate or population screening coverage.
Although positive gonorrhoea results were confirmed
with supplementary tests in 93% (38/41) of LAs, this
occurred after patients were notified about the initial
positive result in 63% (26/41). Approximately 450–4500
confirmed gonorrhoea diagnoses and 2300 false-positive
screens might occur through use of dual tests on NCSP
samples each year. Under reasonable assumptions, the
positive predictive value of the screening test is 17–67%.
Conclusions: Over half of English LAs already
commission dual tests for samples collected by the
NCSP. Gonorrhoea screening has been introduced
alongside chlamydia screening in many low prevalence
settings without a national evidence review or change of
policy. We question the public health benefit here, and
suggest that robust testing algorithms and clinical
management pathways, together with rigorous
evaluation, be implemented wherever dual tests are
deployed.
INTRODUCTION
The English National Chlamydia Screening
Programme (NCSP) offers sexually active,
asymptomatic, women and men, aged 15–
24 years, opportunistic testing to diagnose
and control Chlamydia trachomatis (chla-
mydia) infection in England.1 In 2012, over
1.2 million screening tests were performed
for young people in community-based sexual
health clinics in England (ie, outside of
Strengths and limitations of this study
▪ The English National Chlamydia Screening
Programme (NCSP) aims to diagnose and control
chlamydia in all sexually active people aged 15–
24 years, but no such community-based screen-
ing programme exists for gonorrhoea.
▪ We undertook a national survey of Local Authority
(LA) commissioners of chlamydia screening to
investigate use of dual tests, which simultan-
eously test for chlamydia and gonorrhoea, in
community-based settings (excluding specialist
sexual health services).
▪ Response to the LA survey was high and similar
across the geographical regions in England. There
was no evidence to suggest participation was
associated with area-level Index of Multiple
Deprivation or NCSP characteristics.
▪ The study is limited by the self-reported nature
of the survey responses, which might be subject
to reporting bias. Our data might underestimate
the proportion of LAs using dual tests because
commissioners might not always be aware that
dual tests are being used for NCSP samples.
Most survey questions had item non-response of
around 14%.
▪ In over half of LAs in England, dual tests are
already being used on samples collected by the
NCSP, and in many areas gonorrhoea test results
are returned to patients prior to the result being
confirmed.
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specialist sexual health clinics, called genitourinary
medicine (GUM) clinics in the UK), with over 80 000
chlamydia infections diagnosed.2 Screening is offered by
a variety of providers, including contraception, sexual
health and termination of pregnancy services, pharma-
cies and primary care. Since 2013, commissioning
arrangements have been undertaken through Local
Authorities (LAs), which are regional local government
administrative bodies.3
The test of choice for chlamydia detection is the nucleic
acid ampliﬁcation test (NAAT), and a range of assays, with
extremely high sensitivity and speciﬁcity, are available.4
Many NAATs allow dual detection of chlamydia and
Neisseria gonorrhoeae (gonorrhoea) using a single specimen
and the same assay,4 and it has become inexpensive and
straightforward to simultaneously test for both infections.5
From a simplistic viewpoint, this technological develop-
ment may appear advantageous to public health.5–7
However, new guidance for England on testing for gonor-
rhoea found only sparse evidence for selective community
screening, and no evidence to support widespread unse-
lected screening in community-based settings.8 9 Although
chlamydia and gonorrhoea cause similar disease and
symptoms, there are important differences in the popula-
tion distribution and the microbiology of testing for these
infections that need consideration.10 Unlike chlamydia,
the prevalence of gonorrhoea is very low in the general
population (<0.1% and therefore approximately 10-fold
lower),11 and concentrated in speciﬁc groups (including
those attending specialist GUM clinics).12
Where prevalence is low, the positive predictive value
(PPV) of a single test will also be low, but the problem
of low PPV can be resolved by undertaking a supplemen-
tary test on samples that initially screen positive.
Although the prevalence of gonorrhoea in patients
attending community-based services, such as NSCP set-
tings, might be higher than in the general population
(ranging from 0.3% to 1.7% outside London,6 13–15 and
up to 4.1% in South London),16 lack of proper con-
ﬁrmatory strategies means that the available studies
might overestimate prevalence.9 Together, the low preva-
lence of gonorrhoea and the potential for cross-reaction
with non-gonococcal Neisseria spp. mean that high rates
of false-positive results might occur if gonorrhoea
screening is undertaken on NCSP samples.10
In 2007, a laboratory survey found that 29% of
hospital-based microbiology laboratories in England and
Wales were already using dual tests to diagnose chla-
mydia and gonorrhoea.17 A recent repeat of this survey
suggests that this proportion has increased to 85% (Toby
et al, Public Health England (PHE), unpublished study).
However, it is not known whether this has led to wide-
spread gonorrhoea screening being undertaken on
samples collected by the NCSP. In this study, we (1)
undertook a survey of LA commissioners to understand
the extent to which dual tests are being deployed for
samples collected by the NCSP, (2) collected data about
the clinical care pathways used when gonorrhoea is
detected and (3) linked the survey data with national
surveillance data to estimate the likely number of gonor-
rhoea diagnoses and false-positive gonorrhoea results
occurring in England through the use of dual tests on
samples collected by the NCSP.
METHODS
Survey methodology
During May–July 2013, we delivered an online question-
naire (using the PHE web-based survey tool, ‘Select
Survey’) to commissioners of sexual health services who
were responsible for commissioning chlamydia testing in
people aged 15–24 years for each of the 152 upper tier
LAs in England (upper tier LAs are administrative
bodies with a wide range of local government responsi-
bilities, including public health). Such web-based surveys
are easy to use and maximise response rates.18 The ques-
tionnaire used closed questions and dropdown menus to
ask about: use of dual tests outside of GUM settings (ie,
community-based sexual health screening), service
setting and sample types, use of conﬁrmatory testing
where the screening test was reactive for gonorrhoea,
patient information, and consent processes. Since not all
commissioners were likely to understand technical
molecular deﬁnitions used in relation to conﬁrmatory
testing, the questionnaire used the following pragmatic
deﬁnition for a conﬁrmatory test: “a second test used to
conﬁrm the diagnosis of gonorrhoea where the initial
screening test is positive for gonorrhoea.” The question-
naire was piloted to test usability, understanding, clarity
and question ﬂow; it included 29 questions and took
approximately 20 min to complete. Respondents were
recruited by email using a national list of LA sexual
health commissioners, which covered the whole of
England, and the survey was advertised in the quarterly
NCSP newsletter.
Statistical analysis
Survey data were extracted to Microsoft Excel and a
descriptive analysis was undertaken. The denominator for
descriptive analyses was the number of LAs, which varied
by item non-response. Using Stata (V.12.1), independent
samples t test compared area-level characteristics between
LA responders and non-responders and between LAs
using and not using dual tests. Chlamydia diagnosis rates
(per 100 000 population) and chlamydia testing coverage
included diagnoses and testing in community-based and
GUM settings collected through the Chlamydia Testing
Activity Dataset (CTAD) and the GUM Clinic Activity
Dataset (GUMCAD), and gonorrhoea diagnosis rates (per
100 000 population) included diagnoses made in GUM
clinics collected through GUMCAD.2 19
Estimating the number of gonorrhoea false positives and
confirmed positives
For each LA using dual tests, PHE CTAD2 data on the
number of chlamydia tests performed outside of GUM
2 Field N, et al. BMJ Open 2014;4:e006067. doi:10.1136/bmjopen-2014-006067
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clinics in 2012 was used as a proxy for the total number
of gonorrhoea tests performed through use of dual tests
on samples collected by the NCSP (excluding screening
in GUM). Using this ﬁgure, we estimated the absolute
number of unconﬁrmed reactive tests and the number
of conﬁrmed diagnoses, using published speciﬁcity esti-
mates for a commercial dual test assay.20 We did this for
two scenarios for the overall prevalence of gonorrhoea
in community-based settings, 0.1% and 1%, which repre-
sent plausible minimum and maximum values,
respectively.9 11
Ethics
This work was undertaken with data collected and held
within the requirements of the Data Protection Act and
in accordance with data sharing best practice and PHE
guidelines.21 The study did not use individual patient
data and did not require or seek ethical approval.
RESULTS
LA survey response and use of dual tests
Overall, 98/152 of LAs responded to the survey, which
equates to a response rate across England of 64%
(table 1). The proportion of LAs responding was at least
50% in all 15 PHE centre areas, and the area-level
characteristics of responding and non-responding LAs
were statistically similar. Comparison between respond-
ing and non-responding LAs included area-level Index
of Multiple Deprivation22 (mean Index of Multiple
Deprivation score 22.9 vs 23.1; p=0.89), mean chlamydia
positivity among those testing and aged 15–24 years
(7.9% vs 7.8%; p=0.63), mean chlamydia diagnosis rate
(2152/100 000 vs 1870/100 000; p=0.06), mean chla-
mydia testing coverage among those aged 15–24 years
(27% vs 24%; p=0.06) and mean GUM gonorrhoea diag-
nosis rate estimated from GUM diagnoses (43/100 000
vs 39/100 000; p=0.68) for each LA area.
Over half (53% (52/98)) of responding LAs reported
commissioning use of dual tests for samples collected by
the NCSP, 45% (44/98) had never commissioned dual
tests, and 2% (2/98) had previously commissioned dual
tests or did not know (table 1). Most LAs (82% (37/45))
reported using dual tests in at least ﬁve different
non-GUM settings, including Contraception and Sexual
Health and Sexual and Reproductive Health services
(98% (44/45)) and primary care (91% (41/45)) set-
tings, as well as in termination of pregnancy services
(87% (39/45)) and through remote sample collection
by post or internet (80% (36/45)).
At an area level, there was no signiﬁcant difference in
Index of Multiple Deprivation, chlamydia positivity
among those testing and aged 15–24 years, chlamydia
diagnosis rate, or mean chlamydia testing coverage
among those aged 15–24 years, when comparing LAs
using and not using dual tests (table 2). Mean gonor-
rhoea diagnosis rates based on diagnoses made in GUM
clinics were higher (53 vs 32/100 000; p=0.03) in LAs
using dual tests compared with those not using.
Nevertheless, most LAs had low gonorrhoea diagnosis
rates that were below 50/100 000 (ﬁgure 1). We noted
three LAs where dual tests were not being used, all in
London, where GUM gonorrhoea diagnosis rates were
above 100/100 000, placing these areas inside the top
10% nationally.
Clinical care pathway for gonorrhoea
NCSP standards stipulate that patients should be given
speciﬁc information about any testing that is additional
to chlamydia and that informed consent for such testing
is obtained.23 The standards also recommend that
laboratories should not test for any infection unless this
has been speciﬁcally requested, and that patients diag-
nosed with gonorrhoea in community-based settings
should usually be referred to a GUM clinic.23
Overall, 36% (15/42) of LAs using dual tests reported
providing gonorrhoea-speciﬁc patient information mate-
rials to patients, 45% (19/42) provided no gonorrhoea-
speciﬁc information materials and 19% (8/42) did not
know. Of those without gonorrhoea-speciﬁc patient
information materials, 84% (16/19) reported that gon-
orrhoea was discussed within their NCSP patient infor-
mation leaﬂet, while only 5% (1/19) of these LAs
reported providing no gonorrhoea information (11%
(2/19) did not know). Informed consent for testing of
gonorrhoea was reported as assumed (on the basis that
information was provided and the testing kit was
returned) in 71% (25/35) of LAs, and taken in writing
in 14% (5/35). Three per cent (1/35) of LAs did not
obtain consent.
Although conﬁrmatory testing (deﬁned in the survey
as a second test conﬁrming the diagnosis of gonor-
rhoea) was reported as being used in 93% (38/41) of
LAs, in practice, conﬁrmation only occurred after refer-
ral to specialist sexual health services in most areas. In
total, 63% (26/41) of LAs reported referring patients to
sexual health services on the basis of a reactive screening
test, 17% (7/41) referred after conﬁrmatory testing,
15% (6/41) did not refer patients to another service
and 10% (4/41) did not know.
Estimating the number of false-positive and confirmed
positive gonorrhoea tests
We used the LA survey data, national surveillance data,2
and published data on gonorrhoea prevalence in
community-based settings9 11 to estimate the number of
conﬁrmed gonorrhoea diagnoses and false positives that
might occur each year through the use of dual tests on
samples collected by the NCSP (table 1). Using CTAD
surveillance data from only the 52 LAs that reported
using dual tests, we estimated that at least 456 085
screening tests for gonorrhoea might be undertaken per
year in non-GUM settings in England, which would lead
to around 456 diagnoses of conﬁrmed gonorrhoea per
year if the overall prevalence is 0.1%. In this scenario,
and assuming test sensitivity and speciﬁcity of 99.5%
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Table 1 LA survey response and reported use of dual tests on samples collected by the NCSP for people aged 15–24 years, with estimated numbers of gonorrhoea (NG)
tests performed, confirmed diagnoses, and unconfirmed reactive tests for 2012
PHE region
Number
of LAs
Survey
response,
number
of LAs (%)
LAs (%)
using dual
tests*
Non-GUM
CT tests†
If community-based NG
prevalence is 0.1%
If community-based NG
prevalence is 1.0%
Estimated NG
diagnoses‡
Estimated unconfirmed
reactive NG tests
(PPV=17%)§
Estimated NG
diagnoses‡
Estimated unconfirmed
reactive NG tests
(PPV=67%)§
All 152 98 (64) 52 (53) 456 085 456 2278 4561 2258
London 33 21 (64) 14 (67) 98 250 98 491 983 486
Midlands
and East of
England
35 26 (74) 6 (23) 67 362 67 336 674 333
North of
England
50 34 (68) 21 (62) 194 321 194 971 1943 962
South of
England
34 17 (50) 11 (65) 96 152 96 480 962 476
*Number and percentage of LAs using dual tests out of those responding to the survey.
†Number of non-GUM CT tests performed in all LAs using dual tests as a proxy for the number of gonorrhoea screening tests performed, using data extracted from CTAD which comprises all
chlamydia testing carried out in England.
‡Estimated number of confirmed NG diagnoses arising from use of dual tests on samples collected by the NCSP (non-GUM) if NG prevalence is 0.1% or 1%.
§Estimated number of reactive but unconfirmed NG tests arising from use of dual tests on samples collected by the NCSP (non-GUM) if NG prevalence is 0.1% or 1% and the sensitivity and
specificity of test are 99.5%.
CT, Chlamydia trachomatis; CTAD, Chlamydia Testing Activity Dataset; GUM, genitourinary medicine; LA, Local Authority; NCSP, National Chlamydia (CT) Screening Programme; NG,
Neisseria gonorrhoeae; PPV, positive predictive value.
Table 2 Comparison of area-level characteristics between LAs reporting current commissioning of dual tests and those not*
Number of LAs Mean chlamydia diagnosis rate/100 000† Mean chlamydia testing coverage‡ Mean gonorrhoea diagnosis rate/100 000§
Using dual tests 52 2254.8 28.6% 52.7
Not using dual tests 46 2063.2 26.2% 32.4
p Value difference – 0.31 0.24 0.03
*No significant difference was found by NCSP chlamydia positivity rate (p=0.93), LA Index of Multiple Deprivation (p=0.88), or the proportion of NCSP services provided by GUM or GP, but the
proportion of services provided by CSHS was higher in those LAs using dual tests (19.4% vs 8.6%; (p<0.01)).
†Chlamydia diagnosis rates (per 100 000 population) include diagnoses made in community-based and GUM settings collected through CTAD and GUMCAD.
‡Chlamydia testing coverage includes tests performedin community-based and GUM settings collected through CTAD and GUMCAD.
§Gonorrhoea diagnoses (per 100 000 population) include diagnoses made in GUM clinics collected through GUMCAD.
CSHS, community sexual health services; CTAD, Chlamydia Testing Activity Dataset; GP, general practice; GUM, genitourinary medicine; GUMCAD, GUM Clinic Activity Dataset; LA, Local
Authority; NCSP, National Chlamydia (Chlamydia trachomatis) Screening Programme; PPV, positive predictive value.
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(which is likely to be at the upper end of existing plat-
form speciﬁcity), approximately 2278 false-positive react-
ive screens would occur and the PPV of the screening
test would be 17%. If the true prevalence of gonorrhoea
was 1%, the number of false-positive tests occurring
would be 2258, the number of conﬁrmed diagnoses
would be 4561 and the PPV would be 67%.
DISCUSSION
Statement of principal findings
This is the ﬁrst national study to investigate the use of
dual tests for chlamydia and gonorrhoea on samples col-
lected by the NCSP. Although the NCSP does not recom-
mend simultaneous screening for chlamydia and
gonorrhoea, our data suggest that over half of LAs in
England already commission dual tests for NCSP
samples. Thus, in many areas across England, screening
for asymptomatic gonococcal infection has been intro-
duced in low prevalence settings without a national evi-
dence review or any change in national screening policy.
Furthermore, we found evidence that reactive screening
test results are being returned to patients prior to gonor-
rhoea infection being conﬁrmed. Given that many react-
ive screening tests for gonorrhoea will be false positives
due to low prevalence, this ﬁnding raises considerable
concerns. We question the public health beneﬁt of
deploying dual tests for NCSP samples without careful
consideration of the risks. Commissioners and providers
may need to undertake appropriately powered pilot
studies to decide whether dual tests are appropriate in
their local areas. If dual tests are used, there are import-
ant implications for resource allocation in managing
unconﬁrmed reactive tests and for the personal toll on
an individual’s well-being if the test is not conﬁrmed;
conﬁrmatory tests should be performed before patients
are informed about gonorrhoea diagnoses.
Strengths and weaknesses of the study
Response to the LA survey was high and similar across
the geographical regions in England. There was no evi-
dence to suggest participation bias associated with Index
of Multiple Deprivation or NCSP area-level character-
istics. It therefore seems likely that the responding LAs
are representative of English LAs in their use of dual
tests and that the data are generalisable. However, the
study is limited by the self-reported nature of the survey
responses, which might be subject to reporting bias.
Furthermore, most survey questions had an item non-
response of around 14%, which might reﬂect respon-
dents’ lack of understanding, lack of knowledge about
service speciﬁcations or reluctance to answer questions
that might reveal suboptimal practice. Our data might
underestimate the proportion of LAs using dual tests
because commissioners might not always be aware that
dual tests are being used for NCSP samples.
Although LAs using dual tests were more likely to be
areas with higher rates of gonorrhoea diagnosis made in
GUM clinics, which might indicate evidence-based
policy making, this ﬁnding might also be explained by
increased diagnosis of gonorrhoea in these areas arising
from the introduction of dual tests.
Meaning of the study: possible explanations and
implications for clinicians and policymakers
This study has signiﬁcant implications for commissioners
of sexual health services in LAs and for clinical services
providing chlamydia screening. While screening for gon-
orrhoea in community-based settings might be appropri-
ate in some areas where the prevalence is high, we show
that dual tests are being used in areas where the preva-
lence and PPV are likely to be extremely low. Conversely,
we also show that dual tests are not being used in some
high prevalence areas that might beneﬁt from targeted
gonorrhoea screening.
The increased availability, technical ease, and declin-
ing cost of dual and, in due course, multiplex molecular
testing platforms for sexually transmitted infections
(STIs) make them attractive tools for laboratories that
process high specimen volumes. The emergence of anti-
microbial resistant (AMR) gonorrhoea is a major threat
to global health and these molecular tests offer consider-
able public health beneﬁts by facilitating detection and
control of gonorrhoea.24 However, for commissioners,
policymakers and providers, our study draws attention to
the risk of false-positive test results and the need to
Figure 1 Mean gonorrhoea (NG) diagnoses per 100 000
population (made in GUM clinics) between 2009–2012 by
whether LAs use dual tests on samples collected by the
National Chlamydia Screening Programme (1) Each vertical
dash represents an LA, giving the four year average (2009–
2012) for gonorrhoea diagnoses (per 100 000 population) for
the 98 LAs responding to the survey, including diagnoses
made in GUM clinics collected through GUMCAD (2) Boxes
shows the median and lower and upper quartiles for four year
average gonorrhoea diagnoses in each group. NG, Neisseria
gonorrhoeae; GUM, genitourinary medicine; GUMCAD, GUM
Clinic Activity Dataset; LA, Local Authority; NAAT, nucleic acid
amplification test.
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minimise potential distress caused to patients. The
harms of misdiagnoses include the direct emotional
harm to individual patients arising from incorrect and
stigmatising diagnoses and unnecessary partner notiﬁca-
tion,24 25 as well as the possibility of physical harm in the
rare event that the unnecessary treatment causes side
effects. Indirect harm may occur at a population level
due to avoidable antibiotic usage (with implications for
AMR) and clinical expense. Before any STI screening is
introduced, the evidence on potential harms as well as
beneﬁts should be rigorously assessed and, wherever
screening is introduced, robust testing algorithms and
clinical management pathways implemented. A PHE
toolkit is available to support LA sexual health commis-
sioners in estimating PPVs for gonorrhoea testing in dif-
ferent population groups.26 Essential pathways include
those for obtaining informed consent for testing of gon-
orrhoea and for performing conﬁrmatory testing (using
a supplementary NAAT with a different nucleic acid
target) before returning results to patients or initiating
management. These steps are likely to improve patient
autonomy and safety, and avoid misdiagnosis, unneces-
sary clinical management and their associated costs.
Unanswered questions and future research
This paper highlights a broader issue that decisions about
screening may be driven by the availability of diagnostic
testing platforms rather than the evidence base.24 27 A
WHO synthesis of emerging screening criteria, based on
the Wilson and Yungner criteria, highlights the import-
ance of identifying and responding to a recognised heath
need, deﬁning a target population, scientiﬁc evidence of
screening effectiveness, and ensuring the overall beneﬁts
of screening outweigh the potential harms.28
Molecular-based testing brings considerable public health
opportunities through rapid and highly sensitive detection
of one or more pathogens simultaneously, often using
non-invasive samples, with beneﬁts to individual patients
diagnosed with treatable infections, as well as enhancing
surveillance and prevention efforts.27 29 For example, a
multiplex point of care assay has already been developed
to detect nucleic acid targets for 10 different pathogens.30
The US Food and Drug Administration cleared multiplex
panels for respiratory infections in 2011, indicating a new
era for the diagnosis of respiratory infection.31 However,
there is an onus on healthcare commissioners and provi-
ders to understand the tests being ordered for individual
patients and consider the implications for their deploy-
ment at a population level. The risk is that the availability
and low costs of testing technologies may drive local pol-
icies and lead to inconsistent screening practices that lack
an evidence base.
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